SCHEMBL660493

SCHEMBL660493

CN[C@](C)(C(=O)O)c1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 2/20 0.47
HSD17B10 Q99714 2/20 0.47
PLK1 P53350 1/20 0.45
ACP3 P15309 1/20 0.44
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42
GAA P10253 2/20 0.41
PGR P06401 1/20 0.41
PTGS1 P23219 1/20 0.41
MAPK1 P28482 1/20 0.41
PPARG P37231 3/20 0.41
PPARA Q07869 3/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
PPARD Q03181 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MMP8 P22894 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1878848 1.00 KDM4E (0.47) KDM4EALDH1A1HSD17B10PLK1ACP3
SCHEMBL27507947 1.00 KDM4E (0.47) KDM4EALDH1A1HSD17B10PLK1ACP3
SCHEMBL27702983 0.84 KDM4E (0.45) KDM4EALDH1A1HSD17B10PLK1ACP3
SCHEMBL1471745 0.84 KDM4E (0.45) KDM4EALDH1A1HSD17B10PLK1ACP3
SCHEMBL28546281 0.84 KDM4E (0.45) KDM4EALDH1A1HSD17B10PLK1ACP3
SCHEMBL27479791 0.83 KDM4E (0.44) KDM4EALDH1A1HSD17B10PLK1ACP3
SCHEMBL3004207 0.79 ALDH1A1 (0.48) KDM4EALDH1A1HSD17B10ACP3GAA
SCHEMBL6375660 0.79 ALDH1A1 (0.48) KDM4EALDH1A1HSD17B10ACP3GAA
SCHEMBL1748476 0.79 ALDH1A1 (0.48) KDM4EALDH1A1HSD17B10ACP3GAA
SCHEMBL4592424 0.79 KDM4E (0.53) KDM4EALDH1A1HSD17B10PLK1ACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0699074-B1 THROMBIN INHIBITORS MERCK & CO INC (US) 2002-11-13 EP claimed
US-5672582-A ANTICOAGULANTS; 4-SUBSTITUTED CYCLOHEXYLAMINE DERIVATIVES MERCK & CO., INC. (US) 1997-09-30 US claimed
WO-1996011697-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 1996-04-25 WO claimed
US-20120045393-A1 LHRH-II PEPTIDE ANALOGS BRACCO IMAGING SPA (IT) 2012-02-23 US disclosed
WO-2010107832-A1 LHRH-II PEPTIDE ANALOGS BRACCO IMAGING SPA (IT) 2010-09-23 WO disclosed
US-5672582-A ANTICOAGULANTS; 4-SUBSTITUTED CYCLOHEXYLAMINE DERIVATIVES MERCK & CO., INC. (US) 1997-09-30 US disclosed
WO-1996011697-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 1996-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045393-A1 LHRH-II PEPTIDE ANALOGS LHCGR, GNRHR, FSHR KDM4E 1786/4885ALDH1A1 4273/4885HSD17B10 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.